Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Profile: John Maraganore

Nature Biotechnology volume 25, pages 375–376 (2007)Cite this article

John Maraganore is CEO of an increasingly rare breed of firm—the innovative science-based biotech.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. New York

    Brady Huggett

Authors
  1. Brady Huggett
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Negotiating the RNAi patent thicket

Companies eye slice of age-related macular degeneration market

Silent running: the race to the clinic

Web links

RNAi in focus

Alnylam

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huggett, B. Profile: John Maraganore. Nat Biotechnol 25, 375–376 (2007). https://doi.org/10.1038/nbt0407-375

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0407-375

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing